Marker Therapeutics appoints Kathryn Penkus Corzo to Board; CEO granted 250,000 options

Marker Therapeutics, Inc.

Kathryn Penkus Corzo appointed to Board effective Nov 1, 2025; she brings 30+ years of biopharma leadership.
Corzo currently President/COO of bit.bio; previously Head of Oncology Cell Therapy at Takeda Ventures.
Corzo received 147,611 stock options as non-employee director compensation, vesting over 36 months.
CEO Juan Vera granted 250,000 stock options, vesting annually over 4 years under the 2020 Plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.